AstraZeneca lung cancer combination cuts death risk in Phase III trial
AstraZeneca reported Phase III DeLLphi-305 results for IMFINZI plus tarlatamab-dlle in extensive-stage small cell lung cancer at the ESMO Congress 2026. Median overall survival was 21.1 months with the combination versus 12.7 months with IMFINZI alone, while the combination reduced the risk of death by 58% and disease progression or death by 66%. AstraZeneca said the findings reinforce IMFINZI's role as a backbone immunotherapy in small cell lung cancer.
Why it matters
The results provide AstraZeneca with clinical evidence supporting further use of IMFINZI with tarlatamab-dlle in extensive-stage small cell lung cancer. AstraZeneca said the findings could redefine treatment standards, which may expand the commercial opportunity for its oncology portfolio if the data support regulatory or clinical adoption.
Key facts
- 1The trial reported median overall survival of 21.1 months with IMFINZI plus tarlatamab-dlle versus 12.7 months with IMFINZI alone. stocktitan.net
- 2The combination reduced the risk of death by 58%. stocktitan.net
- 3The combination reduced the risk of disease progression or death by 66%. stocktitan.net
- 4The DeLLphi-305 trial enrolled 282 patients in the combination arm and 281 in the IMFINZI-alone arm for the overall-survival analysis. stocktitan.net
- 5Confirmed objective response rate was 26.4% with the combination versus 4.1% with IMFINZI alone. stocktitan.net
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.